Journal of Medicine and Health Research

EPIDEMIOLOGICAL PROFILE OF COVID-19 INFECTION AND ASSESSMENT OF KNOWLEDGES AND PRACTICES OF ITS BARRIER MEASURES BY THE POPULATION FROM THE EAST CAMEROON REGION

NDOE GUIARO MARCELLIN *

Institute of Medical Research and Medicinal Plants Studies (IMPM), Ministry of Scientific Research and Innovation, Yaounde, Cameroon.

NNANGA LEILA SANDRA

Institute of Medical Research and Medicinal Plants Studies (IMPM), Ministry of Scientific Research and Innovation, Yaounde, Cameroon.

ANKONE ANKONE PLACIDE

District Hospital of Garoua-Boulaï, Garoua-Boulaï, Cameroon.

ASSAMA ANANGUE STEVE

Regional Hospital of Bertoua, Bertoua, Cameroon.

P. ATANGANA MVODO DORINE

Regional Hospital of Bertoua, Bertoua, Cameroon.

O. FAK MOANKONG DANIELLE

Regional Hospital of Bertoua, Bertoua, Cameroon.

BIDIERO ZOTI ELIE

Regional Hospital of Bertoua, Bertoua, Cameroon.

B. MANGA NKOUDOU THIERRY

District Medical Center of Dimako, Dimako, Cameroon.

MEKOUI SUZANNE NATHALIE

District Medical Center of Belabo, Belabo, Cameroon.

GBERI ARNAUD

Africa Humanitarian Action (AHA), Bertoua, Cameroon.

J. P. BILLE BONGA

World Health Organization (WHO), Yaounde, Cameroon.

A. MAMANE MBIDA ALAIN

East Regional Delegation of Public Health, Bertoua, Cameroon.

KAABA MONGO CHARLES

East Regional Delegation of Public Health, Bertoua, Cameroon.

TONYE HAGBE POLICARPE

East Regional Delegation of Public Health, Bertoua, Cameroon.

G. EYIMI ABESSOLO FRANÇOIS

East Regional Delegation of Public Health, Bertoua, Cameroon.

NDI ALOA BIENVENU

East Regional Delegation of Public Health, Bertoua, Cameroon.

ZOUONG NKOMBA WINNIE

East Regional Delegation of Public Health, Bertoua, Cameroon.

MBITA GISLAIN LIONNEL

East Regional Delegation of Public Health, Bertoua, Cameroon.

OUSMAN DEKE PIERRE ALEXIS

East Regional Delegation of Public Health, Bertoua, Cameroon.

MINTOP ANNICET DESIRÉ

East Regional Delegation of Public Health, Bertoua, Cameroon.

*Author to whom correspondence should be addressed.

---

Abstract

Background: On the 05^th April 2020, the first confirmed case of covid-19 infection was registered in the Lom & Djerem division, more precisely in the city of Bertoua (East Region of Cameroon). This alert confirming the presence of covid-19 infection in the region, also stepped up the search for suspected and confirmed cases of covid-19 infection by the rapid intervention and investigation teams (RIIT) set up by the East Regional Delegation of public health, in order to prevent the spread of covid-19 infection in the region and also to ensure the effective care for people already infected. In turn, this situation prompted us to conduct this study with the general objective of highlighting the epidemiological profile of covid-19 infection by determining its prevalence in the East Region of Cameroon and also to assess the knowledges and practices of its barrier measures by the population.

Methods: We conducted a cross-sectional study with prospective data collection from the 05^th April 2020 to the 30^th July 2020 on 1003 participants infected with COVID-19 and also on the persons who had been in contact with them. Our study population was distributed in all the 4 divisions from the East Region of Cameroon, namely Lom & Djerem, Kadey, Haut-Nyong and Boumba & Ngoko. We included in our study, all symptomatic and asymptomatic participants at high risk of infection who had direct or indirect contact with patients infected with COVID-19. The screening for COVID-19 infection was done by taking samples from a nasopharyngeal swab, analyzed either by a rapid diagnostic test (RDT) or by RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) in the laboratory of molecular biology at the Regional Hospital of Bertoua city. The therapeutic protocol used by our participants was Hydroxychloroquine 100 mg + Azithromycin 250 mg + Zinc + Calcium Ca-c1000.

Results: During our study period, we registered 1306 alerts of suspected cases for COVID-19 infection in a general population of 1146981 inhabitants in the East region of Cameroon, among which we identified 1003 cases for COVID-19 infection, for an overall prevalence of 76.8% (95% CI [70.1%-80.3%]). Asymptomatic participants were the most represented with a rate of 65.4% compared to symptomatic participants who represented only 34.6% of cases (P=0.01). The prevalences of these two types of participants (Asymptomatic and Symptomatic) were respectively 50.23% (95% CI [48.21%-53.64%]) and 26.57% (95% CI [24.68% -27.96%]). HIV infection was the most common comorbidity among our participants with a rate of 47.15%. Among the 1003 participants infected with COVID-19 registered in our study, we counted 720 (71.78%) cases of cure after the treatment received, 258 (25.72%) active cases and 25 deaths, for a case fatality rate of 2.5%. 51 cases for COVID-19 infection were registered among healthcare professionals, for a rate of 5.08%.

Conclusion: The contamination of participants in our study was strongly associated with their level of knowledge and practice of barrier measures against Covid-19 infection.

Keywords: Covid-19, comorbidity, symptomatic patient, asymptomatic patient, prevalence, barrier measure.

---

---

---

References

World Health Organisation. Novel Coronavirus (COVID-19) Situation; 2020. Available:http://who.maps.arcgis.com/apps/opsdashboard/index.html#/c88e37cfc43b4ed3baf977d77e4a0667

CDC (3 April 2020). «Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)», dans Centers for Disease Control and Prevention. Available:https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (Accessed: 15 April 2020)

Johns Hopkins University (15 avril 2020). «COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)». Available:https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 (Accessed: 15 avril 2020)

European Centre for Disease Prevention and Control. Novel coronavirus overview.
Available:https://www.ecdc.europa.eu/en/novel-coronavirus-china, https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

MAEP (Mai). Riposte de l'Afrique à la Covid-19 en matière de gouvernance. Rapport préliminaire 2020 ;18. Available:https://au.int/sites/default/files/documents/38893-doc-covid_19_report_final_french.pdf

Zunyou Wu, Jennifer M. McGoogan. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239-1242. DOI: 10.1001/jama.2020.2648

Lewis C. 21 Percent of NYC Residents Tested In State Study Have Antibodies From COVID-19. dans Gothamist; 2020. Available:https://gothamist.com/news/new-york-antibody-testresults-coronavirus (Accessed: 24 April 2020)

Daniel F. Gudbjartsson, Agnar Helgason, Hakon Jonsson, Olafur T. Magnusson, Pall Melsted, Gudmundur L. Norddahl, Jona Saemundsdottir, Asgeir Sigurdsson, Patrick Sulem, Arna B. Agustsdottir, Berglind Eiriksdottir, Run Fridriksdottir et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020;382:2302-2315. DOI: 10.1056/NEJMoa2006100.

Streeck, Bianca Schulte, Beate M. Kümmerer, Enrico Richter, Tobias Höller, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. medRxiv preprint. DOI: 10.1101/2020.05.04.20090076

Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. Nature. 2020;584: 425-429. DOI: 10.1038./s41586-020-2488-1.

Li R, Pei S, Chen B. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19); 2020. DOI: 10.1101/2020.02.14.20023127

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the Asymptomatic Ratio of 2019 Novel Coronavirus onboard the Princess Cruises Ship; 2020. DOI: 10.1101/2020.02.20.20025866

VIH/SIDA à chaque région sa prévalence-CRTV. Available:http://www.crtv.cm/2018/11/vih-sida-a-chaque-region-sa-prevalence/

Marcellin Guiaro Ndoe, Octavie Danielle Moankong Fak, Armel Herve Nwabo Kamdje, Charles Fokunang Ntungwen, Alexandre Michel Njan Nloga. Seroprevalence of Infectious Makers on Blood Donors at the Blood Bank of Bertoua Regional Hospital (Cameroon). Science Journal of Public Health. 2015;3(5):757-760. DOI: 10.11648/j.sjph.20150305.33

Societé Française de Lutte Contre le SIDA (SFLS). Rapport du 13 Mars 2020. Available:https://vih.org/20200313/covid-19-personnes-vivant-avec-le-vih-pas-particulierement-exposees/

Müller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis 2017;76(5): 891- 7.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA.

Feb 07. Available:https://jamanetwork.com/journals/jama/fullarticle/2761044

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020 Feb 09. Available:https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.